Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05006924
Other study ID # 255164
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 2021
Est. completion date December 2026

Study information

Verified date August 2021
Source Oslo University Hospital
Contact Hanne L Fossmo, MSC
Phone +47 93630606
Email halufo@ous-hf.no
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Myotonic Dystrophy type 1 (DM1) is a multisystem disease that causes muscle weakness and myotonia. As a result upper limb function might become impaired. In this study we will examine patients with DM1 and record their upper limb function. We will will use a battery of patient reported outcomes (PROs) and Outcome measures (OMs) in order to evalute which ones are suitable for use in clinical practise and research studies.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date December 2026
Est. primary completion date October 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: • Genetically confirmed Myotonic Dystrophy type 1 Exclusion Criteria: - Unable to answer or understand questionnaires due to language barriers or cognitive status - Unable to perform functional tests

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Norway Haukeland University Hospital Bergen
Norway Oslo University Hispital Oslo
Norway Frambu Centre for Rare Disorders Siggerud

Sponsors (3)

Lead Sponsor Collaborator
Oslo University Hospital Haukeland University Hospital, University of Oslo

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Motor Function Measures (MFM) Functional test 30-45 minutes
Primary Nine Hole Peg Test Fine motor function test 1-3 minutes
Primary Myogrip/Dynamometer Measures hand strenght 1-3 minutes
Primary Myopinch Measures finger strenght 1-3 minutes
Primary ABILHAND Questionnaire A measure of manual ability for adults with upper limb impairments. The scale measures a person's ability to manage daily activities that require the use of the upper limbs, whatever the strategies involved. Consists of 22 questions (18 to be answered by adults). The categories are easy, difficult or unable to perform. The querionnaire gives a sum score where higher score equals better function.Score from 0 to 36 5 min
Primary ACTIVLIM Questionnaire A measure of activity limitations for patients with upper and/or lower limb impairments. The scale measures a patient's ability to perform daily activities requiring the use of the upper and/or the lower limbs, whatever the strategies involved. Consists of 22 questions (18 to be answered by adults). The categories are easy, difficult or unable to perform. The questionnaire gives a sum score where higher score equals better function. Score fror 0 to 36 5 min
Secondary Trunk Impairment Scale - modified Norwegian version Motor impairment of trunk measured by functional testing. Six subdomains measuring stability and mobility of trunkal movement. Min score 0 - Max score 16. Higher score indicates better function. 8-15 minutes
Secondary Four Square Step Test Dynamic balance test 1-3 minutes
Secondary PROMIS29 Questionnaire. Patient reported outcome measure. Generic health related quality of life assesses each of the 7 PROMIS domains (depresseion, anxiety, physical function, pain, fatigue, sleep disturbance and ability to participate in social roles). The PROMIS 29 questionnaire contains 4 questions from each of seven PROMIS contents (physical function, depression, anxiety, fatigue, sleep disorder, participation in social activities and pain interaction) and 1 question from the intensity of pain. Each item has 5 answer options (from 1 to 5), only pain intensity has 11 answer options (from 0 to 10). From the sum of the answers to each question in the domain, the total raw score for each domain is calculated, resulting in seven domain scores, each between 4 and 20. 5-10 minutes
Secondary Starkstein Apathy Scale Questionnaire to be filled in under guidance of interviewer. Patient reported outcome measure of apathy. 14 questions, each of which is scored on a 4-point scale of 0-3, and apathy is rated as severer as the total score (0-42) increases 5 minutes
Secondary Montreal Cognitive Assessment (MoCA) Cognitive assessment screening questionnaire. To be filled out in an interview setting. Score from 0 to 30, where a higher score indicates a better cognitive function. A score of 26 or more is considered normal. 10 minutes
Secondary Lung function test Spirometry with FVC (Forced Vital Capasity) 10 minutes
Secondary Lung function test PEF (Peak Expiratory Flow). 10 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT02880735 - Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy N/A
Recruiting NCT06378216 - Myotonic Dystrophy Type 1 Congenital and Juvenile Form: From Diagnosis to Rehabilitation [MDCJ-NeuBeRe]
Active, not recruiting NCT06089018 - Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Children With Myotonic Dystrophy
Completed NCT05662150 - Low-frequency Repetitive Nerve Stimulation in Myotonic Dystrophy Type 1 N/A
Active, not recruiting NCT04698551 - NIPD on cffDNA for Triplet Repeat Diseases
Completed NCT05027269 - Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients Phase 1/Phase 2
Completed NCT04712422 - Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1
Recruiting NCT04656210 - Myotonic Dystrophy - Vascular and Cognition
Completed NCT04634682 - Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 N/A
Withdrawn NCT06270186 - Evaluation of Cognitive Functions in 20 Patients With Type 1 Myotonic Dystrophy With Virtual Reality Approach N/A
Recruiting NCT06411288 - Global Study of Del-desiran for the Treatment of DM1 Phase 3
Recruiting NCT06300307 - Study of ATX-01 in Participants With DM1 Phase 1/Phase 2
Completed NCT02729597 - Tracking the Brain in Myotonic Dystrophies: a 5-year Longitudinal Follow-up Study N/A
Recruiting NCT06138743 - Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Phase 1
Not yet recruiting NCT05532813 - Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease) Phase 3
Active, not recruiting NCT04886518 - Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Phase 2
Completed NCT05036447 - Myotonic Dystrophy Type 1 and Resistance Exercise N/A
Recruiting NCT03424460 - Venous Thromboembolism in Myotonic Dystrophy Type 1 N/A
Recruiting NCT05865483 - Profile of Dysphagia in Myotonic Dystrophy Type 1 (DM1)
Completed NCT04001920 - Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1 N/A